Pasar al contenido principal

MEDICINA INTERCEPTIVA, DESCUBRIMIENTO DE DIANAS Y REUTILIZACION DE FARMACOS MEDIANTE MODELOS MECANISTICOS Y APRENDIZAJE SUPERVISADO

PID2020-117979RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD, M.P.

Resultados relacionados

Resultados totales (Incluyendo duplicados): 30
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

A crowdsourcing database for the copy-number variation of the Spanish population

  • López-López, Daniel
  • Roldán, Gema
  • Fernández-Rueda, Jose L.
  • Bostelmann, Gerrit
  • Carmona, Rosario
  • Aquino, Virginia
  • Perez-Florido, Javier
  • Ortuño, Francisco José
  • Pita, Guillermo
  • Núñez-Torres, Rocío
  • González Neira, Anna
  • CSVS Crowdsourcing Group
  • Peña-Chilet, María
  • Dopazo, Joaquin
Despite being a very common type of genetic variation, the distribution of copy-number variations (CNVs) in the population is still poorly understood. The knowledge of the genetic variability, especially at the level of the local population, is a critical factor for distinguishing pathogenic from non-pathogenic variation in the discovery of new disease variants. Here, we present the SPAnish Copy Number Alterations Collaborative Server (SPACNACS), which currently contains copy number variation profiles obtained from more than 400 genomes and exomes of unrelated Spanish individuals. By means of a collaborative crowdsourcing effort whole genome and whole exome sequencing data, produced by local genomic projects and for other purposes, is continuously collected. Once checked both, the Spanish ancestry and the lack of kinship with other individuals in the SPACNACS, the CNVs are inferred for these sequences and they are used to populate the database. A web interface allows querying the database with different filters that include ICD10 upper categories. This allows discarding samples from the disease under study and obtaining pseudo-control CNV profiles from the local population. We also show here additional studies on the local impact of CNVs in some phenotypes and on pharmacogenomic variants. SPACNACS can be accessed at: http://csvs.clinbioinfosspa.es/spacnacs/. SPACNACS facilitates disease gene discovery by providing detailed information of the local variability of the population and exemplifies how to reuse genomic data produced for other purposes to build a local reference database., This work is supported by Grants PID2020-117979RB-I00 from the Spanish Ministry of Science and Innovation; by the Institute of Health Carlos III (project IMPaCT-Data, exp. IMP/00019, IMP/00009 and PI20/01305), co-funded by the European Union, European Regional Development Fund (ERDF, “A way to make Europe”).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Drug-target identification in COVID-19 disease mechanisms using computational systems biology approaches

  • Niarakis, Anna
  • Piñero González, Janet, 1977-
  • Furlong, Laura I., 1971-
  • COVID-19 Disease Map Community
Introduction: The COVID-19 Disease Map project is a large-scale community effort uniting 277 scientists from 130 Institutions around the globe. We use high-quality, mechanistic content describing SARS-CoV-2-host interactions and develop interoperable bioinformatic pipelines for novel target identification and drug repurposing. Methods: Extensive community work allowed an impressive step forward in building interfaces between Systems Biology tools and platforms. Our framework can link biomolecules from omics data analysis and computational modelling to dysregulated pathways in a cell-, tissue- or patient-specific manner. Drug repurposing using text mining and AI-assisted analysis identified potential drugs, chemicals and microRNAs that could target the identified key factors. Results: Results revealed drugs already tested for anti-COVID-19 efficacy, providing a mechanistic context for their mode of action, and drugs already in clinical trials for treating other diseases, never tested against COVID-19. Discussion: The key advance is that the proposed framework is versatile and expandable, offering a significant upgrade in the arsenal for virus-host interactions and other complex pathologies., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. AN acknowledges support from SANOFI-AVENTIS R&D via the CIFRE contract, n° 2020/0766. MK, FH, NP, FE, and CE acknowledge the support of the ZonMw COVID-19 programme (Grant No. 10430012010015). JD Spanish Ministry of Science and Innovation (Grant no. PID2020-117979RB-I00) and Instituto de Salud Carlos III (Grant no. IMP/00019). MAi, KK, FS: Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) - Project-ID 251654672 - TRR 161 and under Germany’s Excellence Strategy - EXC 2117 - 422037984. FM: “5 per 1000–2021” grant of the Italian Ministry of Health (Grant No. 5M-2021-23683787) and European Commission with HORIZON programme, BY-COVID project (Grant No. 101046203—BY-COVID). National Institute for Infectious Diseases Lazzaro Spallanzani–IRCCS received financial support from the Italian Ministry of Health grant “Ricerca Corrente”. JP, LF: IMI2-JU grants, resources which are composed of financial contributions from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA [GA: 777365 eTRANSAFE], and the EU H2020 Programme [GA:964537 RISKHUNT3R]; Project 001-P-001647—Valorisation of EGA for Industry and Society funded by the European Regional Development Fund (ERDF) and Generalitat de Catalunya; Institute of Health Carlos III (project IMPaCT-Data, exp. IMP/00019), co-funded by the European Union, European Regional Development Fund (ERDF, “A way to make Europe”). AMo, MP and AV acknowledge the support of the European Commission under the INFORE project (H2020-ICT-825070) and the PerMedCoE (H2020-ICT-951773). Contributions by TH and BLP were supported by NIH grant #R35GM119770 to TH. MaGo acknowledges funding from Deutsche Forschungsgemeinschaft (DFG) through grants no. 442326535 (NFDI4Health) and 451265285 (NFDI4Health Task Force COVID-19), from the European Commission through the Horizon 2020 framework program under grant no. 825843 (EU-STANDS4PM) and through the Digital Europe program under grant no. 101083771 (EDITH), as well as from the Klaus Tschira Foundation. AL acknowledges support from the Intramural Research Program of the National Library of Medicine (NLM), National Institutes of Health (NIH).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

The Spanish Polygenic Score reference distribution: a resource for personalized medicine

  • Carmona, Rosario
  • Roldán, Gema
  • Fernández-Rueda, Jose L.
  • Navarro, Arcadi
  • Peña-Chilet, María
  • CSVS Crowdsourcing Group
  • Dopazo, Joaquín
  • López-López, Daniel
Data de publicació electrònica: 24-04-2025, Here we present the Polygenic Score (PGS) distributions for 3124 common diseases and quantitative traits observed in the Spanish population. To achieve so, the genomes and exomes of 2190 unrelated individuals of Spanish ancestry were used. The analysis covered a wide range of diseases and traits, including both complex disorders, such as various types of cancer, and disorders associated with the digestive, cardiovascular, neuronal, and immune systems, as well as quantitative traits like hematological and anthropometric measurements. The resulting PGS distributions provide valuable insights into the genetic architecture of the Spanish population, offering a comprehensive framework for investigating disease susceptibility and potential risk factors in this specific population. The study has also explored potential relationships between diseases and traits based on PGS pairwise correlations, revealing significant correlations that warrant further investigation. These findings have contributed to increase our understanding of the genetic basis of human traits and have implications for personalized medicine and public health interventions in the Spanish population. In addition, for the sake of reproducibility, we provide a data processing pipeline, enabling the computation of PGS for external genomes and exomes. The pipeline, accessible on GitHub, supports parallel tasks on various computing platforms and contributes to the standardization of PGS comparisons globally. Lastly, a user-friendly web interface facilitates the exploration of PGS reference distributions, featuring a detailed table, distribution plots, and filtering options. This interface enhances accessibility for researchers and clinicians, fostering informed decision-making based on population-specific PGS distributions. The PGS reference distributions can be explored at the SpPGS Atlas repository through the web interface: https://csvs.clinbioinfosspa.es/?tab=pgs., This work is supported by Postdoctoral Grant RH-0052-2021 of Rosario Carmona from Junta de Andalucía (Consejería de Salud y Familias), co-funded by the European Union, European Social Fund (FSE) 2014-2020, and also by grants PID2020-117979RB-I00 from the Spanish Ministry of Science and Innovation, IMPaCT-Data IMP/00019 from the ISCIII, co-funded with European Regional Development Funds (ERDF).
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publicación Artículo científico (JournalArticle)

Detection of High Level of Co-Infection and the Emergence of Novel SARS CoV-2 Delta-Omicron and Omicron-Omicron Recombinants in the Epidemiological Surveillance of Andalusia

  • Perez Florido, Javier
  • Casimiro Soriguer, Carlos S.
  • Ortuño, Francisco
  • Fernandez Rueda, Jose L.
  • Aguado, Andrea
  • Lara, María
  • Riazzo, Cristina
  • Rodríguez Iglesias, Manuel Antonio
  • Camacho Martinez, Pedro
  • Merino Diaz, Laura
  • Pupo Ledo, Inmaculada
  • de Salazar, Adolfo
  • Viñuela, Laura
  • Fuentes, Ana
  • Chueca, Natalia
  • García, Federico
  • Dopazo, Joaquín
  • Lepe, Jose A.
Recombination is an evolutionary strategy to quickly acquire new viral properties inherited from the parental lineages. The systematic survey of the SARS-CoV-2 genome sequences of the Andalusian genomic surveillance strategy has allowed the detection of an unexpectedly high number of co-infections, which constitute the ideal scenario for the emergence of new recombinants. Whole genome sequence of SARS-CoV-2 has been carried out as part of the genomic surveillance programme. Sample sources included the main hospitals in the Andalusia region. In addition to the increase of co-infections and known recombinants, three novel SARS-CoV-2 delta-omicron and omicron-omicron recombinant variants with two break points have been detected. Our observations document an epidemiological scenario in which co-infection and recombination are detected more frequently. Finally, we describe a family case in which co-infection is followed by the detection of a recombinant made from the two co-infecting variants. This increased number of recombinants raises the risk of emergence of recombinant variants with increased transmissibility and pathogenicity., 11 páginas
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Real world evidence of calcifediol or vitamin D prescription and mortality rate of COVID-19 in a retrospective cohort of hospitalized Andalusian patients

  • Loucera, Carlos
  • Peña-Chilet, María
  • Esteban-Medina, Marina
  • Muñoyerro-Muñiz, Dolores
  • Villegas-Portero, Román
  • López-Miranda, José
  • Rodríguez-Baño, Jesús
  • Túnez, Isaac
  • Bouillon, Roger
  • Dopazo, Joaquín
  • Quesada-Gómez, José Manuel
COVID-19 is a major worldwide health problem because of acute respiratory distress syndrome, and mortality. Several lines of evidence have suggested a relationship between the vitamin D endocrine system and severity of COVID-19. We present a survival study on a retrospective cohort of 15,968 patients, comprising all COVID-19 patients hospitalized in Andalusia between January and November 2020. Based on a central registry of electronic health records (the Andalusian Population Health Database, BPS), prescription of vitamin D or its metabolites within 15–30 days before hospitalization were recorded. The effect of prescription of vitamin D (metabolites) for other indication previous to the hospitalization was studied with respect to patient survival. Kaplan–Meier survival curves and hazard ratios support an association between prescription of these metabolites and patient survival. Such association was stronger for calcifediol (Hazard Ratio, HR = 0.67, with 95% confidence interval, CI, of [0.50–0.91]) than for cholecalciferol (HR = 0.75, with 95% CI of [0.61–0.91]), when prescribed 15 days prior hospitalization. Although the relation is maintained, there is a general decrease of this effect when a longer period of 30 days prior hospitalization is considered (calcifediol HR = 0.73, with 95% CI [0.57–0.95] and cholecalciferol HR = 0.88, with 95% CI [0.75, 1.03]), suggesting that association was stronger when the prescription was closer to the hospitalization., This work is supported by grants PID2020-117979RB-I00 from the Spanish Ministry of Science and Innovation, IMP/0019, ACCI2018/29 from CIBERER-ISCIII; COV20/00788 from the Instituto de Salud Carlos III (ISCIII), co-funded with European Regional Development Funds (ERDF); grant G999088Q from the Fundación BBVA; grant H2020 Programme of the European Union grants Marie Curie Innovative Training Network "Machine Learning Frontiers in Precision Medicine" (MLFPM) (GA 813533); P18-RT-3471 from Consejería de Salud y Familias de la Junta de Andalucía; CB16/10/00245, CB16/10/00501 from CIBERFES-ISCIII; PI19/00033 from the ISCIII, co-funded with ERDF; COVID-011-2020 from Consejería de Salud y Familia. The authors also acknowledge Junta de Andalucía for the postdoctoral contract of Carlos Loucera (PAIDI2020- DOC_00350) co-funded by the European Social Fund (FSE) 2014-2020.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk

  • Loucera, Carlos
  • Carmona, Rosario
  • Esteban-Medina, Marina
  • Bostelmann, Gerrit
  • Muñoyerro-Muñiz, Dolores
  • Villegas-Portero, Román
  • Peña-Chilet, María
  • Dopazo, Joaquín
Despite the extensive vaccination campaigns in many countries, COVID-19 is still a major worldwide health problem because of its associated morbidity and mortality. Therefore, finding efficient treatments as fast as possible is a pressing need. Drug repurposing constitutes a convenient alternative when the need for new drugs in an unexpected medical scenario is urgent, as is the case with COVID-19. Using data from a central registry of electronic health records (the Andalusian Population Health Database, BPS), the effect of prior consumption of drugs for other indications previous to the hospitalization with respect to patient survival was studied on a retrospective cohort of 15,968 individuals, comprising all COVID-19 patients hospitalized in Andalusia between January and November 2020. Covariate-adjusted hazard ratios and analysis of lymphocyte progression curves support a significant association between consumption of 21 different drugs and better patient survival. Contrarily, one drug, furosemide, displayed a significant increase in patient mortality., This research was funded by Spanish Ministry of Science and Innovation (grant PID2020- 117979RB-I00), the Instituto de Salud Carlos III (ISCIII), co-funded with European Regional Development Funds (ERDF) (grant IMP/00019), and has also been funded by Consejería de Salud y Familias, Junta de Andalucía (grants COVID-0012-2020, PS-2020-342 and IE19_259 FPS) and the postdoctoral contract of Carlos Loucera (PAIDI2020- DOC_00350) co-funded by the European Social Fund (FSE) 2014-2020., No
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Assessing the Impact of SARS-CoV-2 Lineages and Mutations on Patient Survival

  • Loucera, Carlos
  • Pérez-Florido, Javier
  • Casimiro-Soriguer, Carlos S.
  • Ortuño, Francisco M.
  • Carmona, Rosario
  • Bostelmann, Gerrit
  • Martínez-González, Luis Javier
  • Muñoyerro-Muñiz, Dolores
  • Villegas-Portero, Román
  • Rodríguez-Baño, Jesús
  • Romero-Gómez, Manuel
  • Lorusso, Nicola
  • García-León, Francisco Javier
  • Navarro-Marí, José María
  • Camacho‐Martínez, Pedro
  • Merino Díaz, Laura
  • Salazar, Adolfo de
  • Viñuela, Laura
  • The Andalusian COVID-19 Sequencing Initiative
  • Lepe, José A.
  • García, Federico
  • Dopazo, Joaquín
Objectives: More than two years into the COVID-19 pandemic, SARS-CoV-2 still remains a global public health problem. Successive waves of infection have produced new SARS-CoV-2 variants with new mutations for which the impact on COVID-19 severity and patient survival is uncertain. Methods: A total of 764 SARS-CoV-2 genomes, sequenced from COVID-19 patients, hospitalized from 19th February 2020 to 30 April 2021, along with their clinical data, were used for survival analysis. Results: A significant association of B.1.1.7, the alpha lineage, with patient mortality (log hazard ratio (LHR) = 0.51, C.I. = [0.14,0.88]) was found upon adjustment by all the covariates known to affect COVID-19 prognosis. Moreover, survival analysis of mutations in the SARS-CoV-2 genome revealed 27 of them were significantly associated with higher mortality of patients. Most of these mutations were located in the genes coding for the S, ORF8, and N proteins. Conclusions: This study illustrates how a combination of genomic and clinical data can provide solid evidence for the impact of viral lineage on patient survival., This work was supported by Spanish Ministry of Science and Innovation (grant PID2020- 117979RB-I00), the Instituto de Salud Carlos III (ISCIII), co-funded with European Regional Development Funds (ERDF) (grant IMP/00019), and has also been funded by Consejería de Salud y Familias, Junta de Andalucía (grants COVID-0012-2020 and PS-2020-342) and the postdoctoral contract of Carlos Loucera (PAIDI2020- DOC_00350), co-funded by the European Social Fund (FSE) 2014-2020. ELIXIR-CONVERGE—H2020 (871075)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Discovering potential interactions between rare diseases and COVID-19 by combining mechanistic models of viral infection with statistical modeling

  • López-Sánchez, Macarena
  • Loucera, Carlos
  • Peña-Chilet, María
  • Dopazo, Joaquín
Recent studies have demonstrated a relevant role of the host genetics in the coronavirus disease 2019 (COVID-19) prognosis. Most of the 7000 rare diseases described to date have a genetic component, typically highly penetrant. However, this vast spectrum of genetic variability remains yet unexplored with respect to possible interactions with COVID-19. Here, a mathematical mechanistic model of the COVID-19 molecular disease mechanism has been used to detect potential interactions between rare disease genes and the COVID-19 infection process and downstream consequences. Out of the 2518 disease genes analyzed, causative of 3854 rare diseases, a total of 254 genes have a direct effect on the COVID-19 molecular disease mechanism and 207 have an indirect effect revealed by a significant strong correlation. This remarkable potential of interaction occurs for >300 rare diseases. Mechanistic modeling of COVID-19 disease map has allowed a holistic systematic analysis of the potential interactions between the loss of function in known rare disease genes and the pathological consequences of COVID-19 infection. The results identify links between disease genes and COVID-19 hallmarks and demonstrate the usefulness of the proposed approach for future preventive measures in some rare diseases., Spanish Ministry of Science and Innovation (PID2020-117979RB-I00); Centro de Investigación Biomédica En Red de Enfermedades Raras-Instituto de Salud Carlos III (ACCI2018/29); Instituto de Salud Carlos III (ISCIII), co-funded with European Regional Development Funds (ERDF) (IMP/0019 and COV20/00788); Fundación Banco Bilbao Vizcaya Argentaria (grant G999088Q); grant H2020 Programme of the European Union grants Marie Curie Innovative Training Network ‘Machine Learning Frontiers in Precision Medicine’ (MLFPM; GA 813533); Consejería de Salud y Familias de la Junta de Andalucía (P18-RT-3471); ISCIII (PI20/01305), co-funded with ERDF; Consejería de Salud y Familia (COVID-011-2020); Junta de Andalucía for the postdoctoral contract of Carlos Loucera (PAIDI2020-DOC_00350) co-funded by the European Social Fund (FSE) 2014–2020., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Integrating pathway knowledge with deep neural networks to reduce the dimensionality in single-cell RNA-seq data

  • Gundogdu, Pelin
  • Loucera, Carlos
  • Alamo-Alvarez, Inmaculada
  • Dopazo, Joaquín
  • Nepomuceno, Isabel
[Background] Single-cell RNA sequencing (scRNA-seq) data provide valuable insights into cellular heterogeneity which is significantly improving the current knowledge on biology and human disease. One of the main applications of scRNA-seq data analysis is the identification of new cell types and cell states. Deep neural networks (DNNs) are among the best methods to address this problem. However, this performance comes with the trade-off for a lack of interpretability in the results. In this work we propose an intelligible pathway-driven neural network to correctly solve cell-type related problems at single-cell resolution while providing a biologically meaningful representation of the data., [Results] In this study, we explored the deep neural networks constrained by several types of prior biological information, e.g. signaling pathway information, as a way to reduce the dimensionality of the scRNA-seq data. We have tested the proposed biologically-based architectures on thousands of cells of human and mouse origin across a collection of public datasets in order to check the performance of the model. Specifically, we tested the architecture across different validation scenarios that try to mimic how unknown cell types are clustered by the DNN and how it correctly annotates cell types by querying a database in a retrieval problem. Moreover, our approach demonstrated to be comparable to other less interpretable DNN approaches constrained by using protein-protein interactions gene regulation data. Finally, we show how the latent structure learned by the network could be used to visualize and to interpret the composition of human single cell datasets., [Conclusions] Here we demonstrate how the integration of pathways, which convey fundamental information on functional relationships between genes, with DNNs, that provide an excellent classification framework, results in an excellent alternative to learn a biologically meaningful representation of scRNA-seq data. In addition, the introduction of prior biological knowledge in the DNN reduces the size of the network architecture. Comparative results demonstrate a superior performance of this approach with respect to other similar approaches. As an additional advantage, the use of pathways within the DNN structure enables easy interpretability of the results by connecting features to cell functionalities by means of the pathway nodes, as demonstrated with an example with human melanoma tumor cells., This work is supported by grants PID2020-117979RB-I00 from the Spanish Ministry of Science and Innovation, IMP/0019 from the Instituto de Salud Carlos III (ISCIII), co-funded with European Regional Development Funds (ERDF); grant H2020 Programme of the European Union grants Marie Curie Innovative Training Network “Machine Learning Frontiers in Precision Medicine” (MLFPM) (GA 813533); The authors also acknowledge Junta de Andalucía for the postdoctoral contract of Carlos Loucera (PAIDI2020- DOC_00350) co-funded by the European Social Fund (FSE) 2014–2020., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Towards a metagenomics machine learning interpretable model for understanding the transition from adenoma to colorectal cancer

  • Casimiro-Soriguer, Carlos S.
  • Loucera, Carlos
  • Peña-Chilet, María
  • Dopazo, Joaquín
Gut microbiome is gaining interest because of its links with several diseases, including colorectal cancer (CRC), as well as the possibility of being used to obtain non-intrusive predictive disease biomarkers. Here we performed a meta-analysis of 1042 fecal metagenomic samples from seven publicly available studies. We used an interpretable machine learning approach based on functional profiles, instead of the conventional taxonomic profiles, to produce a highly accurate predictor of CRC with better precision than those of previous proposals. Moreover, this approach is also able to discriminate samples with adenoma, which makes this approach very promising for CRC prevention by detecting early stages in which intervention is easier and more effective. In addition, interpretable machine learning methods allow extracting features relevant for the classification, which reveals basic molecular mechanisms accounting for the changes undergone by the microbiome functional landscape in the transition from healthy gut to adenoma and CRC conditions. Functional profiles have demonstrated superior accuracy in predicting CRC and adenoma conditions than taxonomic profiles and additionally, in a context of explainable machine learning, provide useful hints on the molecular mechanisms operating in the microbiota behind these conditions., This work is supported by Grants PID2020-117979RB-I00 from the Spanish Ministry of Science and Innovation and PI20/01305 and IMP/0019 from the ISCIII, both co-funded with European Regional Development Funds (ERDF) as well as H2020 Programme of the European Union Grants Marie Curie Innovative Training Network "Machine Learning Frontiers in Precision Medicine" (MLFPM) (GA 813533) and “ELIXIR-EXCELERATE fast-track ELIXIR implementation and drive early user exploitation across the life sciences” (GA 676559). The postdoctoral contract for CL PAIDI2020- DOC_00350 is funded by Junta de Andalucía and co-funded by the European Social Fund (FSE) 2014-2020., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Crosstalk between Metabolite Production and Signaling Activity in Breast Cancer

  • Çubuk, Cankut
  • Loucera, Carlos
  • Peña-Chilet, María
  • Dopazo, Joaquín
The reprogramming of metabolism is a recognized cancer hallmark. It is well known that different signaling pathways regulate and orchestrate this reprogramming that contributes to cancer initiation and development. However, recent evidence is accumulating, suggesting that several metabolites could play a relevant role in regulating signaling pathways. To assess the potential role of metabolites in the regulation of signaling pathways, both metabolic and signaling pathway activities of Breast invasive Carcinoma (BRCA) have been modeled using mechanistic models. Gaussian Processes, powerful machine learning methods, were used in combination with SHapley Additive exPlanations (SHAP), a recent methodology that conveys causality, to obtain potential causal relationships between the production of metabolites and the regulation of signaling pathways. A total of 317 metabolites were found to have a strong impact on signaling circuits. The results presented here point to the existence of a complex crosstalk between signaling and metabolic pathways more complex than previously was thought., This research was funded by Spanish Ministry of Science and Innovation, grant numbers PID2020-117979RB-I00 and grants IMP/00019 and PI20/01305 from the Instituto de Salud Carlos III (ISCIII), co-funded with European Regional Development Funds (ERDF), and has also been funded by Junta de Andalucía with grant PE-0002-2018 and the postdoctoral contract of Carlos Loucera (PAIDI2020-DOC_00350) co-funded by the European Social Fund (FSE) 2014–2020., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Detection of High Level of Co-Infection and the Emergence of Novel SARS CoV-2 Delta-Omicron and Omicron-Omicron Recombinants in the Epidemiological Surveillance of Andalusia

  • Pérez-Florido, Javier
  • Casimiro-Soriguer, Carlos S.
  • Ortuño, Francisco M.
  • Fernández-Rueda, José L.
  • Aguado, Andrea
  • Lara, María
  • Riazzo, Cristina
  • Rodríguez-Iglesias, Manuel
  • Camacho‐Martínez, Pedro
  • Merino Díaz, Laura
  • Pupo Ledo, María Inmaculada
  • Salazar, Adolfo de
  • Viñuela, Laura
  • Fuentes, Ana
  • Chueca, Natalia
  • Andalusian Covid-Sequencing Initiative
  • García, Federico
  • Dopazo, Joaquín
  • Lepe, José A.
Recombination is an evolutionary strategy to quickly acquire new viral properties inherited from the parental lineages. The systematic survey of the SARS-CoV-2 genome sequences of the Andalusian genomic surveillance strategy has allowed the detection of an unexpectedly high number of co-infections, which constitute the ideal scenario for the emergence of new recombinants. Whole genome sequence of SARS-CoV-2 has been carried out as part of the genomic surveillance programme. Sample sources included the main hospitals in the Andalusia region. In addition to the increase of co-infections and known recombinants, three novel SARS-CoV-2 delta-omicron and omicron-omicron recombinant variants with two break points have been detected. Our observations document an epidemiological scenario in which co-infection and recombination are detected more frequently. Finally, we describe a family case in which co-infection is followed by the detection of a recombinant made from the two co-infecting variants. This increased number of recombinants raises the risk of emergence of recombinant variants with increased transmissibility and pathogenicity., This research was funded by Spanish Ministry of Science and Innovation (grant PID2020-117979RB-I00), the Instituto de Salud Carlos III (ISCIII), co-funded with European Regional Development Funds (ERDF) (grant IMP/00019), and has also been funded by Consejería de Salud y Familias, Junta de Andalucía (grants COVID-0012-2020, PS-2020-342 and IE19_259 FPS)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Molecular and phylogenetic characterization of the monkeypox outbreak in the South of Spain

  • Casimiro-Soriguer, Carlos S.
  • Pérez-Florido, Javier
  • Lara, María
  • Camacho‐Martínez, Pedro
  • Merino Díaz, Laura
  • Pupo Ledo, María Inmaculada
  • Salazar, Adolfo de
  • Fuentes, Ana
  • Viñuela, Laura
  • Chueca, Natalia
  • Martínez-Martínez, Luis
  • Lorusso, Nicola
  • Andalusian Genomic Surveillance Network
  • Lepe, José A.
  • Dopazo, Joaquín
  • García, Federico
Until the May 2022 Monkeypox outbreak, which spread rapidly to many non-endemic countries, the virus was considered a viral zoonosis limited to some African countries. The Andalusian circuit of genomic surveillance was rapidly applied to characterize the Monkeypox outbreak in the South of Spain. Whole genome sequencing was used to obtain the genomic profiles of samples collected across the south of Spain, representative of all the provinces of Andalusia. Phylogenetic analysis was used to study the relationship of the isolates and the available sequences of the 2022 outbreak. Whole genome sequencing of a total of 160 monkeypox viruses from the different provinces that reported cases were obtained. Interestingly, we report the sequences of monkeypox viruses obtained from two patients who died. While one of the isolates bore no noteworthy mutations that explain a potential heightened virulence, in another patient the second consecutive genome sequence, performed after the administration of tecovirimat, uncovered a mutation within the A0A7H0DN30 gene, known to be a prime target for tecovirimat in its Vaccinia counterpart. In general, a low number of mutations were observed in the sequences reported, which were very similar to the reference of the 2022 outbreak (OX044336), as expected from a DNA virus. The samples likely correspond to several introductions of the circulating monkeypox viruses from the last outbreak. The virus sequenced from one of the two patients that died presented a mutation in a gene that bears potential connections to drug resistance. This mutation was absent in the initial sequencing prior to treatment, This work was supported by Spanish Ministry of Science and Innovation (grants PID2020- 117979RB-I00 and FJC2021-046546-I), the Instituto de Salud Carlos III (ISCIII), co-funded with European Regional Development Funds (ERDF) (grant IMP/00019), it has also been funded by Consejería de Salud y Consumo, Junta de Andalucía (grants COVID-0012-2020), and by grant ELIXIR-CONVERGE - Connect and align ELIXIR Nodes to deliver sustainable FAIR lifescience data management services (AMD-871075-16), funded by EU – H2020., No
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

SigPrimedNet: A Signaling-Informed Neural Network for scRNA-seq Annotation of Known and Unknown Cell Types

  • Gundogdu, Pelin
  • Alamo-Alvarez, Inmaculada
  • Nepomuceno-Chamorro, Isabel A.
  • Dopazo, Joaquín
  • Loucera, Carlos
Single-cell RNA sequencing is increasing our understanding of the behavior of complex tissues or organs, by providing unprecedented details on the complex cell type landscape at the level of individual cells. Cell type definition and functional annotation are key steps to understanding the molecular processes behind the underlying cellular communication machinery. However, the exponential growth of scRNA-seq data has made the task of manually annotating cells unfeasible, due not only to an unparalleled resolution of the technology but to an ever-increasing heterogeneity of the data. Many supervised and unsupervised methods have been proposed to automatically annotate cells. Supervised approaches for cell-type annotation outperform unsupervised methods except when new (unknown) cell types are present. Here, we introduce SigPrimedNet an artificial neural network approach that leverages (i) efficient training by means of a sparsity-inducing signaling circuits-informed layer, (ii) feature representation learning through supervised training, and (iii) unknown cell-type identification by fitting an anomaly detection method on the learned representation. We show that SigPrimedNet can efficiently annotate known cell types while keeping a low false-positive rate for unseen cells across a set of publicly available datasets. In addition, the learned representation acts as a proxy for signaling circuit activity measurements, which provide useful estimations of the cell functionalities., This work is supported by grants PID2020-117979RB-I00 and PID2020-117954RB-C22 from the Spanish Ministry of Science and Innovation, IMP/0019 from the Instituto de Salud Carlos III (ISCIII), co-funded with European Regional Development Funds (ERDF); grant H2020 Programme of the European Union grants Marie Curie Innovative Training Network “Machine Learning Frontiers in Precision Medicine” (MLFPM) (GA 813533). The authors also acknowledge Junta de Andalucía for the postdoctoral contract of Carlos Loucera (PAIDI2020-DOC_00350) co-funded by the European Social Fund (FSE) 2014–2020., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A crowdsourcing database for the copy-number variation of the Spanish population

  • López-López, Daniel
  • Roldán, Gema
  • Fernández-Rueda, José L.
  • Bostelmann, Gerrit
  • Carmona, Rosario
  • Aquino, Virginia
  • Pérez-Florido, Javier
  • Ortuño, Francisco
  • Pita, Guillermo
  • Núñez-Torres, Rocío
  • González-Neira, Anna
  • CSVS Crowdsourcing Group
  • Peña-Chilet, María
  • Dopazo, Joaquín
© The Author(s) 2023. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data., [Background] Despite being a very common type of genetic variation, the distribution of copy-number variations (CNVs) in the population is still poorly understood. The knowledge of the genetic variability, especially at the level of the local population, is a critical factor for distinguishing pathogenic from non-pathogenic variation in the discovery of new disease variants., [Results] Here, we present the SPAnish Copy Number Alterations Collaborative Server (SPACNACS), which currently contains copy number variation profiles obtained from more than 400 genomes and exomes of unrelated Spanish individuals. By means of a collaborative crowdsourcing effort whole genome and whole exome sequencing data, produced by local genomic projects and for other purposes, is continuously collected. Once checked both, the Spanish ancestry and the lack of kinship with other individuals in the SPACNACS, the CNVs are inferred for these sequences and they are used to populate the database. A web interface allows querying the database with different filters that include ICD10 upper categories. This allows discarding samples from the disease under study and obtaining pseudo-control CNV profiles from the local population. We also show here additional studies on the local impact of CNVs in some phenotypes and on pharmacogenomic variants. SPACNACS can be accessed at: http://csvs.clinbioinfosspa.es/spacnacs/., [Conclusion] SPACNACS facilitates disease gene discovery by providing detailed information of the local variability of the population and exemplifies how to reuse genomic data produced for other purposes to build a local reference database., This work is supported by Grants PID2020-117979RB-I00 from the Spanish Ministry of Science and Innovation; by the Institute of Health Carlos III (project IMPaCT-Data, exp. IMP/00019, IMP/00009 and PI20/01305), co-funded by the European Union, European Regional Development Fund (ERDF, “A way to make Europe”)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Functional Profiling of Soft Tissue Sarcoma Using Mechanistic Models

  • Payá-Milans, Miriam
  • Peña-Chilet, María
  • Loucera, Carlos
  • Esteban-Medina, Marina
  • Dopazo, Joaquín
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., Soft tissue sarcoma is an umbrella term for a group of rare cancers that are difficult to treat. In addition to surgery, neoadjuvant chemotherapy has shown the potential to downstage tumors and prevent micrometastases. However, finding effective therapeutic targets remains a research challenge. Here, a previously developed computational approach called mechanistic models of signaling pathways has been employed to unravel the impact of observed changes at the gene expression level on the ultimate functional behavior of cells. In the context of such a mechanistic model, RNA-Seq counts sourced from the Recount3 resource, from The Cancer Genome Atlas (TCGA) Sarcoma project, and non-diseased sarcomagenic tissues from the Genotype-Tissue Expression (GTEx) project were utilized to investigate signal transduction activity through signaling pathways. This approach provides a precise view of the relationship between sarcoma patient survival and the signaling landscape in tumors and their environment. Despite the distinct regulatory alterations observed in each sarcoma subtype, this study identified 13 signaling circuits, or elementary sub-pathways triggering specific cell functions, present across all subtypes, belonging to eight signaling pathways, which served as predictors for patient survival. Additionally, nine signaling circuits from five signaling pathways that highlighted the modifications tumor samples underwent in comparison to normal tissues were found. These results describe the protective role of the immune system, suggesting an anti-tumorigenic effect in the tumor microenvironment, in the process of tumor cell detachment and migration, or the dysregulation of ion homeostasis. Also, the analysis of signaling circuit intermediary proteins suggests multiple strategies for therapy., This work was supported by the International Accelerator Award funded by Cancer Research UK [C56167/A29363], Associazione Italiana per la Ricerca sul Cancro [AIRC—24297] and Fundación Científica—Asociación Española Contra el Cáncer [Foundation AECC—GEACC19007MA], the Spanish Ministerio de Ciencia e Innovación (PID2020-117979RB-I00), and the Instituto de Salud Carlos III (ISCIII) (PI20-01305). The authors also acknowledge Junta de Andalucía for the postdoctoral contract of Carlos Loucera (PAIDI2020-DOC_00350), co-funded by the European Social Fund (FSE) 2014–2020., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Real-world evidence with a retrospective cohort of 15,968 COVID-19 hospitalized patients suggests 21 new effective treatments

  • Loucera, Carlos
  • Carmona, Rosario
  • Esteban-Medina, Marina
  • Bostelmann, Gerrit
  • Muñoyerro-Muñiz, Dolores
  • Villegas, Román
  • Peña-Chilet, María
  • Dopazo, Joaquín
© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data., [Purpose] Despite the extensive vaccination campaigns in many countries, COVID-19 is still a major worldwide health problem because of its associated morbidity and mortality. Therefore, finding efficient treatments as fast as possible is a pressing need. Drug repurposing constitutes a convenient alternative when the need for new drugs in an unexpected medical scenario is urgent, as is the case with COVID-19., [Methods] Using data from a central registry of electronic health records (the Andalusian Population Health Database), the effect of prior consumption of drugs for other indications previous to the hospitalization with respect to patient outcomes, including survival and lymphocyte progression, was studied on a retrospective cohort of 15,968 individuals, comprising all COVID-19 patients hospitalized in Andalusia between January and November 2020., [Results] Covariate-adjusted hazard ratios and analysis of lymphocyte progression curves support a significant association between consumption of 21 different drugs and better patient survival. Contrarily, one drug, furosemide, displayed a significant increase in patient mortality., [Conclusions] In this study we have taken advantage of the availability of a regional clinical database to study the effect of drugs, which patients were taking for other indications, on their survival. The large size of the database allowed us to control covariates effectively., This research was funded by Spanish Ministry of Science and Innovation (grant PID2020-117979RB-I00), the Instituto de Salud Carlos III (ISCIII), co-funded with European Regional Development Funds (ERDF) (grant IMP/00019), and has also been funded by Consejería de Salud y Consumo, Junta de Andalucía (grants COVID-0012-2020, PS-2020-342 and IE19_259 FPS) and the postdoctoral contract of Carlos Loucera (PAIDI2020- DOC_00350) co-funded by the European Social Fund (FSE) 2014–2020., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Datos de investigación Set de datos (Dataset)

Supplementary Material: Real-world evidence with a retrospective cohort of 15,968 COVID-19 hospitalized patients suggests 21 new effective treatments

  • Loucera, Carlos
  • Carmona, Rosario
  • Esteban-Medina, Marina
  • Bostelmann, Gerrit
  • Muñoyerro-Muñiz, Dolores
  • Villegas, Román
  • Peña-Chilet, María
  • Dopazo, Joaquín
Supplementary Tables: Table S1. Data imported from BPS for each patient: code and definition of the variable.-- Table S2: Log Hazard ratios obtained for the drugs tested, along with standard deviations (SDs), upper and lower coefficient intervals (CI), nominal and FDR-adjusted p-values. Also, Lymphocyte proliferation values (see Methods) along with standard deviations (SDs), upper and lower coefficient intervals (CI), nominal and FDR-adjusted p-values. The two last columns indicate the drugs used in the machine learning drug repurposing prediction study and the proteins targeted by the drug. Targets marked with an * were those analyzed in the machine learning drug repurposing., [Purpose] Despite the extensive vaccination campaigns in many countries, COVID-19 is still a major worldwide health problem because of its associated morbidity and mortality. Therefore, finding efficient treatments as fast as possible is a pressing need. Drug repurposing constitutes a convenient alternative when the need for new drugs in an unexpected medical scenario is urgent, as is the case with COVID-19., [Methods] Using data from a central registry of electronic health records (the Andalusian Population Health Database), the effect of prior consumption of drugs for other indications previous to the hospitalization with respect to patient outcomes, including survival and lymphocyte progression, was studied on a retrospective cohort of 15,968 individuals, comprising all COVID-19 patients hospitalized in Andalusia between January and November 2020., [Results] Covariate-adjusted hazard ratios and analysis of lymphocyte progression curves support a significant association between consumption of 21 different drugs and better patient survival. Contrarily, one drug, furosemide, displayed a significant increase in patient mortality., [Conclusions] In this study we have taken advantage of the availability of a regional clinical database to study the effect of drugs, which patients were taking for other indications, on their survival. The large size of the database allowed us to control covariates effectively., This research was funded by Spanish Ministry of Science and Innovation (grant PID2020-117979RB-I00), the Instituto de Salud Carlos III (ISCIII), co-funded with European Regional Development Funds (ERDF) (grant IMP/00019), and has also been funded by Consejería de Salud y Consumo, Junta de Andalucía (grants COVID-0012-2020, PS-2020-342 and IE19_259 FPS) and the postdoctoral contract of Carlos Loucera (PAIDI2020- DOC_00350) co-funded by the European Social Fund (FSE) 2014–2020., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Drug-target identification in COVID-19 disease mechanisms using computational systems biology approaches

  • Niarakis, Anna
  • Ostaszewski, Marek
  • Mazein, Alexander
  • Kuperstein, Inna
  • Kutmon, Martina
  • Gillespie, Marc E.
  • Funahashi, Akira
  • Acencio, Marcio Luis
  • Hemedan, Ahmed
  • Aichem, Michael
  • Klein, Karsten
  • Czauderna, Tobias
  • Burtscher, Felicia
  • Yamada, Takahiro G.
  • Hiki, Yusuke
  • Hiroi, Noriko F.
  • Hu, Finterly
  • Pham, Nhung
  • Ehrhart, Friederike
  • Willighagen, Egon L.
  • Valdeolivas, Alberto
  • Dugourd, Aurelien
  • Messina, Francesco
  • Esteban-Medina, Marina
  • Peña-Chilet, María
  • Rian, Kinza
  • Soliman, Sylvain
  • Aghamiri, Sara Sadat
  • Lal Puniya, Bhanwar
  • Naldi, Aurelien
  • Helikar, Tomas
  • Singh, Vidisha
  • Fariñas Fernández, Marco
  • Bermudez, Viviam
  • Tsirvouli, Eirini
  • Montagud, Arnau
  • Noël, Vincent
  • Ponce de León, Miguel
  • Maier, Dieter
  • Bauch, Angela
  • Gyori, Benjamin M.
  • Bachman, John A.
  • Luna, Augustin
  • Piñero, Janet
  • Furlong, Laura I.
  • Balaur, Irina BalaurIrina
  • Rougny, Adrien
  • Jarosz, Yohan
  • Overall, Rupert W.
  • Phair, Robert
  • Perfetto, Livia
  • Matthews, Lisa
  • Balaya Rex, Devasahayam Arokia
  • Orlic-Milacic, Marija
  • Monraz Gómez, Luis Cristóbal
  • De Meulder, Bertrand
  • Ravel, Jean-Marie
  • Jassal, Bijay
  • Satagopam, Venkata
  • Wu, Guanming
  • Golebiewski, Martin
  • Gawron, Piotr
  • Calzone, Laurence
  • Beckmann, Jacques S.
  • Evelo, Chris T.
  • D’Eustachio, Peter
  • Schreiber, Falk
  • Sáez-Rodríguez, Julio
  • Dopazo, Joaquín
  • Kuiper, Martin
  • Valencia, Alfonso
  • Wolkenhauer, Olaf
  • Kitano, Hiroaki
  • Barillot, Emmanuel
  • Auffray, Charles
  • Balling, Rudi
  • Schneider, Reinhard
  • COVID- Disease Map Community the COVID-19 Disease Map Community
© 2024 Niarakis, Ostaszewski, Mazein, Kuperstein, Kutmon, Gillespie, Funahashi, Acencio, Hemedan, Aichem, Klein, Czauderna, Burtscher, Yamada, Hiki, Hiroi, Hu, Pham, Ehrhart, Willighagen, Valdeolivas, Dugourd, Messina, Esteban-Medina, Peña-Chilet, Rian, Soliman, Aghamiri, Puniya, Naldi, Helikar, Singh, Fernández, Bermudez, Tsirvouli, Montagud, Noël, Ponce-de-Leon, Maier, Bauch, Gyori, Bachman, Luna, Piñero, Furlong, Balaur, Rougny, Jarosz, Overall, Phair, Perfetto, Matthews, Rex, Orlic-Milacic, Gomez, De Meulder, Ravel, Jassal, Satagopam, Wu, Golebiewski, Gawron, Calzone, Beckmann, Evelo, D’Eustachio, Schreiber, Saez-Rodriguez, Dopazo, Kuiper, Valencia, Wolkenhauer, Kitano, Barillot, Auffray, Balling, Schneider and the COVID-19 Disease Map Community. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms., Introduction: The COVID-19 Disease Map project is a large-scale community effort uniting 277 scientists from 130 Institutions around the globe. We use high-quality, mechanistic content describing SARS-CoV-2-host interactions and develop interoperable bioinformatic pipelines for novel target identification and drug repurposing., Methods: Extensive community work allowed an impressive step forward in building interfaces between Systems Biology tools and platforms. Our framework can link biomolecules from omics data analysis and computational modelling to dysregulated pathways in a cell-, tissue- or patient-specific manner. Drug repurposing using text mining and AI-assisted analysis identified potential drugs, chemicals and microRNAs that could target the identified key factors., Results: Results revealed drugs already tested for anti-COVID-19 efficacy, providing a mechanistic context for their mode of action, and drugs already in clinical trials for treating other diseases, never tested against COVID-19., Discussion: The key advance is that the proposed framework is versatile and expandable, offering a significant upgrade in the arsenal for virus-host interactions and other complex pathologies., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. AN acknowledges support from SANOFI-AVENTIS R&D via the CIFRE contract, n° 2020/0766. MK, FH, NP, FE, and CE acknowledge the support of the ZonMw COVID-19 programme (Grant No. 10430012010015). JD Spanish Ministry of Science and Innovation (Grant no. PID2020-117979RB-I00) and Instituto de Salud Carlos III (Grant no. IMP/00019). MAi, KK, FS: Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) - Project-ID 251654672 - TRR 161 and under Germany’s Excellence Strategy - EXC 2117 - 422037984. FM: “5 per 1000–2021” grant of the Italian Ministry of Health (Grant No. 5M-2021-23683787) and European Commission with HORIZON programme, BY-COVID project (Grant No. 101046203—BY-COVID). National Institute for Infectious Diseases Lazzaro Spallanzani–IRCCS received financial support from the Italian Ministry of Health grant “Ricerca Corrente”. JP, LF: IMI2-JU grants, resources which are composed of financial contributions from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA [GA: 777365 eTRANSAFE], and the EU H2020 Programme [GA:964537 RISKHUNT3R]; Project 001-P-001647—Valorisation of EGA for Industry and Society funded by the European Regional Development Fund (ERDF) and Generalitat de Catalunya; Institute of Health Carlos III (project IMPaCT-Data, exp. IMP/00019), co-funded by the European Union, European Regional Development Fund (ERDF, “A way to make Europe”). AMo, MP and AV acknowledge the support of the European Commission under the INFORE project (H2020-ICT-825070) and the PerMedCoE (H2020-ICT-951773). Contributions by TH and BLP were supported by NIH grant #R35GM119770 to TH. MaGo acknowledges funding from Deutsche Forschungsgemeinschaft (DFG) through grants no. 442326535 (NFDI4Health) and 451265285 (NFDI4Health Task Force COVID-19), from the European Commission through the Horizon 2020 framework program under grant no. 825843 (EU-STANDS4PM) and through the Digital Europe program under grant no. 101083771 (EDITH), as well as from the Klaus Tschira Foundation. AL acknowledges support from the Intramural Research Program of the National Library of Medicine (NLM), National Institutes of Health (NIH)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The mechanistic functional landscape of retinitis pigmentosa: a machine learning-driven approach to therapeutic target discovery

  • Esteban-Medina, Marina
  • Loucera, Carlos
  • Rian, Kinza
  • Velasco, Sheyla
  • Olivares-González, Lorena
  • Rodrigo, Regina
  • Dopazo, Joaquín
  • Peña-Chilet, María
© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data., [Background] Retinitis pigmentosa is the prevailing genetic cause of blindness in developed nations with no effective treatments. In the pursuit of unraveling the intricate dynamics underlying this complex disease, mechanistic models emerge as a tool of proven efficiency rooted in systems biology, to elucidate the interplay between RP genes and their mechanisms. The integration of mechanistic models and drug-target interactions under the umbrella of machine learning methodologies provides a multifaceted approach that can boost the discovery of novel therapeutic targets, facilitating further drug repurposing in RP., [Methods] By mapping Retinitis Pigmentosa-related genes (obtained from Orphanet, OMIM and HPO databases) onto KEGG signaling pathways, a collection of signaling functional circuits encompassing Retinitis Pigmentosa molecular mechanisms was defined. Next, a mechanistic model of the so-defined disease map, where the effects of interventions can be simulated, was built. Then, an explainable multi-output random forest regressor was trained using normal tissue transcriptomic data to learn causal connections between targets of approved drugs from DrugBank and the functional circuits of the mechanistic disease map. Selected target genes involvement were validated on rd10 mice, a murine model of Retinitis Pigmentosa., [Results] A mechanistic functional map of Retinitis Pigmentosa was constructed resulting in 226 functional circuits belonging to 40 KEGG signaling pathways. The method predicted 109 targets of approved drugs in use with a potential effect over circuits corresponding to nine hallmarks identified. Five of those targets were selected and experimentally validated in rd10 mice: Gabre, Gabra1 (GABARα1 protein), Slc12a5 (KCC2 protein), Grin1 (NR1 protein) and Glr2a. As a result, we provide a resource to evaluate the potential impact of drug target genes in Retinitis Pigmentosa., [Conclusions] The possibility of building actionable disease models in combination with machine learning algorithms to learn causal drug-disease interactions opens new avenues for boosting drug discovery. Such mechanistically-based hypotheses can guide and accelerate the experimental validations prioritizing drug target candidates. In this work, a mechanistic model describing the functional disease map of Retinitis Pigmentosa was developed, identifying five promising therapeutic candidates targeted by approved drug. Further experimental validation will demonstrate the efficiency of this approach for a systematic application to other rare diseases., This work is supported by grants PID2020-117979RB-I00 from the Spanish Ministry of Science and Innovation, ACCI2018/29 from CIBER-ISCIII, PI2020/01305, PI22/00082 and project IMPaCT-Data IMP/00019 from the ISCIII, co-funded with European Regional Development Funds (ERDF), the grant “Large-scale drug repurposing in rare diseases by genomic Big Data analysis with machine learning methods” from the Fundación BBVA (G999088Q), the H2020 Programme of the European Union grants Marie Curie Innovative Training Network “Machine Learning Frontiers in Precision Medicine” (MLFPM) (GA 813533), grant P18-RT-3471 from Consejeria de Salud y Consumo, Junta de Andalucia, and grant PIP-0087-2021 from Junta de Andalucía, co-funded with European Regional Development Funds (ERDF). The authors also acknowledge Junta de Andalucía for the postdoctoral contract of Carlos Loucera (PAIDI2020-DOC_00350) co-funded by the European Social Fund (FSE) 2014–2020. SV was funded by a Conselleria de Innovación, Universidades, Ciencia y Sociedad, GVA predoctoral contract (ACIF/2021/430)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Aripiprazole as protector against COVID-19 mortality

  • Loucera, Carlos
  • Canal-Rivero, Manuel
  • Ruiz‐Veguilla, Miguel
  • Rarmona, Rosario
  • Bostelmann, Gerrit
  • Garrido-Torres, Nathalia
  • Dopazo, Joaquín
  • Crespo-Facorro, Benedicto
The relation of antipsychotics with severe Coronavirus Disease 19 (COVID-19) outcomes is a matter of debate since the beginning of the pandemic. To date, controversial results have been published on this issue. We aimed to prove whether antipsychotics might exert adverse or protective effects against fatal outcomes derived from COVID-19. A population-based retrospective cohort study (January 2020 to November 2020) comprising inpatients (15,968 patients) who were at least 18 years old and had a laboratory-confirmed COVID-19 infection. Two sub-cohorts were delineated, comprising a total of 2536 inpatients: individuals who either had no prescription medication or were prescribed an antipsychotic within the 15 days preceding hospitalization. We conducted survival and odds ratio analyses to assess the association between antipsychotic use and mortality, reporting both unadjusted and covariate-adjusted results. We computed the average treatment effects, using the untreated group as the reference, and the average treatment effect on the treated, focusing solely on the antipsychotic-treated population. Among the eight antipsychotics found to be in use, only aripiprazole showed a significant decrease in the risk of death from COVID-19 [adjusted odds ratio (OR) = 0.86; 95% CI, 0.79-0.93, multiple-testing adjusted p-value < 0.05]. Importantly, these findings were consistent for both covariate-adjusted and unadjusted analyses. Aripiprazole has been shown to have a differentiated beneficial effect in protecting against fatal clinical outcome in COVID-19 infected individuals. We speculate that the differential effect of aripiprazole on controlling immunological pathways and inducible inflammatory enzymes, that are critical in COVID19 illness, may be associated with our findings herein., This work is supported by grants PID2020-117979RB-I00 and TED2021-132346B-I00 from the Spanish Ministry of Science and Innovation, IMPaCT-Data IMP/00019 from the ISCIII, co-funded with European Regional Development Funds (ERDF)., MCR works as Clinical Psychologist at Virgen del Rocío University Hospital (Seville, Spain) via Consejería de Salud y Familias (Junta de Andalucía) 2020 grant which covers his salary (RH-0081-2020)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Molecular and phylogenetic characterization of the monkeypox outbreak in the South of Spain

  • Casimiro-Soriguer, Carlos S.
  • Pérez-Florido, Javier
  • Lara, María
  • Camacho‐Martínez, Pedro
  • Merino Díaz, Laura
  • Pupo Ledo, María Inmaculada
  • de Salazar, Adolfo
  • Fuentes, Ana
  • Viñuela, Laura
  • Chueca, Natalia
  • Martínez-Martínez, Luis
  • Lorusso, Nicola
  • Lepe, José A.
  • Dopazo, Joaquín
  • García, Federico
[Background and Aim] Until the May 2022 Monkeypox (MPXV) outbreak, which spread rapidly to many non-endemic countries, the virus was considered a viral zoonosis limited to some African countries. The Andalusian circuit of genomic surveillance was rapidly applied to characterize the MPXV outbreak in the South of Spain., [Methods] Whole genome sequencing was used to obtain the genomic profiles of samples collected across the south of Spain, representative of all the provinces of Andalusia. Phylogenetic analysis was used to study the relationship of the isolates and the available sequences of the 2022 outbreak., [Results] Whole genome sequencing of a total of 160 MPXV viruses from the different provinces that reported cases were obtained. Interestingly, we report the sequences of MPXV viruses obtained from two patients who died. While one of the isolates bore no noteworthy mutations that explain a potential heightened virulence, in another patient the second consecutive genome sequence, performed after the administration of tecovirimat, uncovered a mutation within the A0A7H0DN30 gene, known to be a prime target for tecovirimat in its Vaccinia counterpart. In general, a low number of mutations were observed in the sequences reported, which were very similar to the reference of the 2022 outbreak (OX044336), as expected from a DNA virus. The samples likely correspond to several introductions of the circulating MPXV viruses from the last outbreak. The virus sequenced from one of the two patients that died presented a mutation in a gene that bears potential connections to drug resistance. This mutation was absent in the initial sequencing before treatment., This work was supported by Spanish Ministry of Science and Innovation (grants PID2020-117979RB-I00 and FJC2021-046546-I), the Instituto de Salud Carlos III (ISCIII), cofunded with European Regional Development Funds (ERDF) (grant IMP/00019), it has also been funded by Consejería de Salud y Consumo, Junta de Andalucía (grants COVID-0012-2020), and by grant ELIXIR-CONVERGE-Connect and align ELIXIR Nodes to deliver sustainable FAIR lifescience data management services (AMD-871075-16), funded by EU–H2020., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The Iberian Roma Population Variant Server (IRPVS)

  • Mavillard, Fabiola
  • Pérez-Florido, Javier
  • Ortuño, Francisco M.
  • Valladares, Amador
  • Álvarez-Villegas, Miren L.
  • Roldán, Gema
  • Carmona, Rosario
  • Soriano, Manuel
  • Susarte, Santiago
  • Fuentes, Pilar
  • López-López, Daniel
  • Nuñez-Negrillo, Ana María
  • Carvajal, Alejandra
  • Morgado, Yolanda
  • Arteaga, Daniel
  • Ufano, Rosa
  • Mir, Pablo
  • Gamella, Juan F.
  • Dopazo, Joaquín
  • Paradas, Carmen
  • Cabrera-Serrano, Macarena
In recent years, the number of known disease genes has exponentially grown due to the widespread adoption of cost-effective massive parallel sequencing. To identify new disease variants, especially in monogenic disorders, a frequency-based filtering approach has proved very useful (Dopazo et al., 2016). Evidence suggests that disease susceptibility is linked to low-frequency variants (Tennessen et al., 2012) which are often specific to distinct populations (Wiszniewski et al., 2013). Population-specific databases have been developed (Boomsma et al., 2014; Dopazo et al., 2016; Pena-Chilet et al., 2021), often subdivided by ethnic background or geographical origin (Karczewski et al., 2020), including information for founder populations like Ashkenazi or Amish. However, for the Roma, the largest ethnic minority in Europe and comprising 10 to 12 million people, there is no reference data on genetic variant frequency publicly available to be consulted, which renders them in a situation of disadvantage and inequality., This study has been funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union (grants PI16/00612 and PI20/01200 to MCS) and Junta de Andalucia-Consejeria de Salud y Consumo (grant PIER-0468-2019 to MCS). MCS has been supported by ISCIII (JR15/00042) and Junta de Andalucia-Consejeria de Salud y Consumo (B-0005-2017). JD has been supported by grants PID2020-117979RB-I00 from the Spanish Ministry of Science and Innovation and IMP/00019 from the Instituto de Salud Carlos III (ISCIII). RC has been supported by Junta de Andalucía-Consejería de Salud y Familias (RH-0052-2021) co-funded by the European Union, European Social Fund (FSE) 2014–2020., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Ethical and secure evidence generation from regionwide clinical data through a collaborative environment for advancing predictive care

  • Muñoyerro-Muñiz, Dolores
  • Villegas-Portero, Román
  • Oliva, Víctor de la
  • Esteban-Medina, Alberto
  • Fernández Del Valle, Patricia
  • Sánchez, Ana
  • Susin, M. Belén
  • Gutierrez-Álvarez, Isidoro
  • Reboredo, Marta
  • Alejos, Laura
  • Loucera, Carlos
  • Dopazo, Joaquín
This article is part of the Research Topic: Electronic Health Records in Emergency Medicine: From Accountability to Opportunity., Ensuring data protection is a major challenge in clinical research involving sensitive patient information. However, secure processing environments (SPEs) enable the ethical and compliant secondary use of real-world data (RWD) for evidence generation. This study presents a collaborative infrastructure integrating a comprehensive Health Population Database (BPS) with a legal and computational framework to facilitate secure, large-scale clinical studies. The Andalusian Platform for Medical Evidence Generation is an SPE embedded within the Andalusian healthcare network, leveraging RWD from over 15 million patients from the BPS. It supports diverse studies, including treatment efficacy, survival analyses, and predictive modeling, while ensuring alignment with the General Data Protection Regulation (GDPR) and proactively designed to meet forthcoming European Health Data Space (EHDS) requirements. Data are processed within a secure ecosystem, preventing unauthorized access and enabling legally compliant research collaborations. By combining clinical RWD with a robust ethical and legal framework, we present a scalable model for secure, data-driven region-level healthcare innovation. The platform supports cost-effective predictive models, particularly relevant for aging populations, and establishes a blueprint for regional and international adaptation. This approach strengthens the role of healthcare systems in both knowledge generation and sustainable economic growth, ensuring that patient data is leveraged for scientific and societal benefit., The author(s) declare that financial support was received for the research and/or publication of this article. This work has been co-financed by the Spanish Ministry of Science and Innovation with funds from the European Union NextGenerationEU (PRTR-C17.I1) and the Regional Ministry of University, Research and Innovation of the Autonomous Community of Andalusia within the framework of the Biotechnology Plan applied to Health. It is also supported by the Spanish Ministry of Science and Innovation (PID2020-117979RB-I00, PID2023-152380OB-C21, TED2021-132346B-I00), by the Instituto de Salud Carlos III (ISCIII), co-funded with European Regional Development Funds (IMP/00019, PMP24/00024), and by the Consejeria de Salud y Consumo, Junta de Andalucia (IE19_259 FPS)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The Spanish Polygenic Score reference distribution: a resource for personalized medicine

  • Carmona, Rosario
  • Roldán, Gema
  • Fernández-Rueda, Jose L.
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Peña-Chilet, María
  • CSVS Crowdsourcing Group
  • Dopazo, Joaquín
  • López-López, Daniel
Data de publicació electrònica: 24-04-2025, Here we present the Polygenic Score (PGS) distributions for 3124 common diseases and quantitative traits observed in the Spanish population. To achieve so, the genomes and exomes of 2190 unrelated individuals of Spanish ancestry were used. The analysis covered a wide range of diseases and traits, including both complex disorders, such as various types of cancer, and disorders associated with the digestive, cardiovascular, neuronal, and immune systems, as well as quantitative traits like hematological and anthropometric measurements. The resulting PGS distributions provide valuable insights into the genetic architecture of the Spanish population, offering a comprehensive framework for investigating disease susceptibility and potential risk factors in this specific population. The study has also explored potential relationships between diseases and traits based on PGS pairwise correlations, revealing significant correlations that warrant further investigation. These findings have contributed to increase our understanding of the genetic basis of human traits and have implications for personalized medicine and public health interventions in the Spanish population. In addition, for the sake of reproducibility, we provide a data processing pipeline, enabling the computation of PGS for external genomes and exomes. The pipeline, accessible on GitHub, supports parallel tasks on various computing platforms and contributes to the standardization of PGS comparisons globally. Lastly, a user-friendly web interface facilitates the exploration of PGS reference distributions, featuring a detailed table, distribution plots, and filtering options. This interface enhances accessibility for researchers and clinicians, fostering informed decision-making based on population-specific PGS distributions. The PGS reference distributions can be explored at the SpPGS Atlas repository through the web interface: https://csvs.clinbioinfosspa.es/?tab=pgs., This work is supported by Postdoctoral Grant RH-0052-2021 of Rosario Carmona from Junta de Andalucía (Consejería de Salud y Familias), co-funded by the European Union, European Social Fund (FSE) 2014-2020, and also by grants PID2020-117979RB-I00 from the Spanish Ministry of Science and Innovation, IMPaCT-Data IMP/00019 from the ISCIII, co-funded with European Regional Development Funds (ERDF).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A crowdsourcing database for the copy-number variation of the Spanish population

  • López-López, Daniel
  • Roldán, Gema
  • Fernández-Rueda, Jose L.
  • Bostelmann, Gerrit
  • Carmona, Rosario
  • Aquino, Virginia
  • Perez-Florido, Javier
  • Ortuño, Francisco José
  • Pita, Guillermo
  • Núñez-Torres, Rocío
  • González Neira, Anna
  • CSVS Crowdsourcing Group
  • Peña-Chilet, María
  • Dopazo, Joaquin
Despite being a very common type of genetic variation, the distribution of copy-number variations (CNVs) in the population is still poorly understood. The knowledge of the genetic variability, especially at the level of the local population, is a critical factor for distinguishing pathogenic from non-pathogenic variation in the discovery of new disease variants. Here, we present the SPAnish Copy Number Alterations Collaborative Server (SPACNACS), which currently contains copy number variation profiles obtained from more than 400 genomes and exomes of unrelated Spanish individuals. By means of a collaborative crowdsourcing effort whole genome and whole exome sequencing data, produced by local genomic projects and for other purposes, is continuously collected. Once checked both, the Spanish ancestry and the lack of kinship with other individuals in the SPACNACS, the CNVs are inferred for these sequences and they are used to populate the database. A web interface allows querying the database with different filters that include ICD10 upper categories. This allows discarding samples from the disease under study and obtaining pseudo-control CNV profiles from the local population. We also show here additional studies on the local impact of CNVs in some phenotypes and on pharmacogenomic variants. SPACNACS can be accessed at: http://csvs.clinbioinfosspa.es/spacnacs/. SPACNACS facilitates disease gene discovery by providing detailed information of the local variability of the population and exemplifies how to reuse genomic data produced for other purposes to build a local reference database., This work is supported by Grants PID2020-117979RB-I00 from the Spanish Ministry of Science and Innovation; by the Institute of Health Carlos III (project IMPaCT-Data, exp. IMP/00019, IMP/00009 and PI20/01305), co-funded by the European Union, European Regional Development Fund (ERDF, “A way to make Europe”).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Drug-target identification in COVID-19 disease mechanisms using computational systems biology approaches

  • Niarakis, Anna
  • Piñero González, Janet, 1977-
  • Furlong, Laura I., 1971-
  • COVID-19 Disease Map Community
Introduction: The COVID-19 Disease Map project is a large-scale community effort uniting 277 scientists from 130 Institutions around the globe. We use high-quality, mechanistic content describing SARS-CoV-2-host interactions and develop interoperable bioinformatic pipelines for novel target identification and drug repurposing. Methods: Extensive community work allowed an impressive step forward in building interfaces between Systems Biology tools and platforms. Our framework can link biomolecules from omics data analysis and computational modelling to dysregulated pathways in a cell-, tissue- or patient-specific manner. Drug repurposing using text mining and AI-assisted analysis identified potential drugs, chemicals and microRNAs that could target the identified key factors. Results: Results revealed drugs already tested for anti-COVID-19 efficacy, providing a mechanistic context for their mode of action, and drugs already in clinical trials for treating other diseases, never tested against COVID-19. Discussion: The key advance is that the proposed framework is versatile and expandable, offering a significant upgrade in the arsenal for virus-host interactions and other complex pathologies., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. AN acknowledges support from SANOFI-AVENTIS R&D via the CIFRE contract, n° 2020/0766. MK, FH, NP, FE, and CE acknowledge the support of the ZonMw COVID-19 programme (Grant No. 10430012010015). JD Spanish Ministry of Science and Innovation (Grant no. PID2020-117979RB-I00) and Instituto de Salud Carlos III (Grant no. IMP/00019). MAi, KK, FS: Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) - Project-ID 251654672 - TRR 161 and under Germany’s Excellence Strategy - EXC 2117 - 422037984. FM: “5 per 1000–2021” grant of the Italian Ministry of Health (Grant No. 5M-2021-23683787) and European Commission with HORIZON programme, BY-COVID project (Grant No. 101046203—BY-COVID). National Institute for Infectious Diseases Lazzaro Spallanzani–IRCCS received financial support from the Italian Ministry of Health grant “Ricerca Corrente”. JP, LF: IMI2-JU grants, resources which are composed of financial contributions from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA [GA: 777365 eTRANSAFE], and the EU H2020 Programme [GA:964537 RISKHUNT3R]; Project 001-P-001647—Valorisation of EGA for Industry and Society funded by the European Regional Development Fund (ERDF) and Generalitat de Catalunya; Institute of Health Carlos III (project IMPaCT-Data, exp. IMP/00019), co-funded by the European Union, European Regional Development Fund (ERDF, “A way to make Europe”). AMo, MP and AV acknowledge the support of the European Commission under the INFORE project (H2020-ICT-825070) and the PerMedCoE (H2020-ICT-951773). Contributions by TH and BLP were supported by NIH grant #R35GM119770 to TH. MaGo acknowledges funding from Deutsche Forschungsgemeinschaft (DFG) through grants no. 442326535 (NFDI4Health) and 451265285 (NFDI4Health Task Force COVID-19), from the European Commission through the Horizon 2020 framework program under grant no. 825843 (EU-STANDS4PM) and through the Digital Europe program under grant no. 101083771 (EDITH), as well as from the Klaus Tschira Foundation. AL acknowledges support from the Intramural Research Program of the National Library of Medicine (NLM), National Institutes of Health (NIH).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A crowdsourcing database for the copy-number variation of the Spanish population

  • López López, Daniel|||0000-0001-7672-7335
  • Roldán, Gema
  • Fernández-Rueda, Jose L.
  • Bostelmann, Gerrit|||0000-0002-1690-6347
  • Carmona, Rosario|||0000-0003-2563-9591
  • Aquino, Virginia|||0000-0002-2329-8159
  • Pérez-Florido, Javier|||0000-0002-0223-9889
  • Ortuño, Francisco Manuel|||0000-0001-7424-1753
  • Pita, Guillermo|||0000-0003-2393-0510
  • Núñez Torres, Rocío|||0000-0003-1752-2756
  • González-Neira, Anna
  • Peña-Chilet, María|||0000-0002-6445-9617
  • Dopazo, Joaquín|||0000-0003-3318-120X
  • Alonso, Ángel|||0000-0001-5111-310X
  • Salgado-Garrido, Josefa|||0000-0002-2764-8507
  • Pasalodos-Sanchez, Sara
  • Ayuso, Carmen|||0000-0002-9606-6957
  • Minguez, Pablo|||0000-0003-4099-9421
  • Avila-Fernandez, Almudena
  • Corton, Marta|||0000-0003-0087-1626
  • Artuch, R.|||0000-0002-3422-9685
  • Borrego, Salud|||0000-0002-2513-6161
  • Antiñolo Gil, Guillermo|||0000-0002-2113-074X
  • Carracedo, Ángel|||0000-0003-1085-8986
  • Amigo, Jorge|||0000-0002-1362-2605
  • Castaño, Luis|||0000-0003-0437-9401
  • Tejada, María Isabel|||0000-0002-7334-1864
  • Delmiro, Aitor
  • Espinos, Carmina
  • Grinberg, Daniel|||0000-0001-9859-2590
  • Guillén-Navarro, Encarna|||0000-0002-2915-7381
  • Lapunzina, Pablo|||0000-0002-6324-4825
  • López-Escámez, Jose Antonio|||0000-0002-8583-1430
  • Gallego-Martínez, Álvaro|||0000-0002-6068-8965
  • Martí, Ramon A.|||0000-0002-8273-9540
  • Rovira-Moreno, Eulalia|||0000-0001-5483-7031
  • Millán, José María
  • Moreno-Pelayo, Miguel Ángel|||0000-0003-3839-5098
  • Morin, Matías|||0000-0002-7985-592X
  • Moreno Galdó, Antonio|||0000-0002-2496-9786
  • Fernández Cancio, Mónica|||0000-0003-1872-3488
  • Morte, Beatriz|||0000-0003-0702-7815
  • Mulero, Victoriano
  • García, Diana
  • Nunes Martínez, Virginia|||0000-0002-5747-9310
  • Palau, Francesc|||0000-0002-8635-5421
  • Pérez, Belén|||0000-0001-5801-1704
  • Pérez-Jurado, Luis Alberto|||0000-0002-1988-3005
  • Perona, Rosario|||0000-0002-2973-5153
  • Pujol, Aurora|||0000-0002-9606-0600
  • Ramos, Feliciano
  • López, Esther
  • Ribes i Rubió, Antònia|||0000-0002-2249-246X
  • Rosell Andreo, Jordi
  • Surralles, Jordi|||0000-0002-4041-7519
Background: Despite being a very common type of genetic variation, the distribution of copy-number variations (CNVs) in the population is still poorly understood. The knowledge of the genetic variability, especially at the level of the local population, is a critical factor for distinguishing pathogenic from non-pathogenic variation in the discovery of new disease variants. Results: Here, we present the SPAnish Copy Number Alterations Collaborative Server (SPACNACS), which currently contains copy number variation profiles obtained from more than 400 genomes and exomes of unrelated Spanish individuals. By means of a collaborative crowdsourcing effort whole genome and whole exome sequencing data, produced by local genomic projects and for other purposes, is continuously collected. Once checked both, the Spanish ancestry and the lack of kinship with other individuals in the SPACNACS, the CNVs are inferred for these sequences and they are used to populate the database. A web interface allows querying the database with different filters that include ICD10 upper categories. This allows discarding samples from the disease under study and obtaining pseudo-control CNV profiles from the local population. We also show here additional studies on the local impact of CNVs in some phenotypes and on pharmacogenomic variants. SPACNACS can be accessed at: http://csvs.clinbioinfosspa.es/spacnacs/. Conclusion: SPACNACS facilitates disease gene discovery by providing detailed information of the local variability of the population and exemplifies how to reuse genomic data produced for other purposes to build a local reference database.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

The Spanish Polygenic Score reference distribution: a resource for personalized medicine

  • Carmona, Rosario
  • Roldán, Gema
  • Fernández-Rueda, José L.
  • Navarro, Arcadi
  • Peña-Chilet, María
  • Alonso Sánchez, Ángel Miguel
  • Salgado Garrido, Josefa
  • Pasalodos Sánchez, Sara
  • Aquino, Virginia
  • Pérez-Florido, Javier
  • Bostelmann, Gerrit
  • Ayuso, Carmen
  • Mínguez, Pablo
  • Ávila-Fernández, Almudena
  • Corton, Marta
  • Artuch, Rafael
  • Borrego, Salud
  • Antiñolo, Guillermo
  • Carracedo, Ángel
  • Amigo, Jorge
  • Castaño, Luis Antonio
  • Tejada, Isabel
  • Delmiro, Aitor
  • Espinos, Carmina
  • Grinberg, Daniel
  • Guillén, Encarnación
  • Lapunzina, Pablo
  • López-Escámez, José Antonio
  • Gallego-Martínez, Álvaro
  • Martí, Ramón
  • Rovira, Eulalia
  • Millán, José María
  • Moreno Pelayo, Miguel Ángel
  • Morín, Matías
  • Moreno-Galdó, Antonio
  • Fernández-Cancio, Mónica
  • Morte, Beatriz
  • Mulero, Victoriano
  • García, Diana
  • Nunes, Virginia
  • Palau, Francesc
  • Pérez, Belén
  • Perona, Rosario
  • Pujol, Aurora
  • Ramos, Feliciano
  • López, Esther
  • Ribes, Antonia
  • Rosell, Jordi
  • Surrallés, Jordi
  • Dopazo, Joaquín
  • López-López, Daniel
Here we present the Polygenic Score (PGS) distributions for 3124 common diseases and quantitative traits observed in the Spanish population. To achieve so, the genomes and exomes of 2190 unrelated individuals of Spanish ancestry were used. The analysis covered a wide range of diseases and traits, including both complex disorders, such as various types of cancer, and disorders associated with the digestive, cardiovascular, neuronal, and immune systems, as well as quantitative traits like hematological and anthropometric measurements. The resulting PGS distributions provide valuable insights into the genetic architecture of the Spanish population, offering a comprehensive framework for investigating disease susceptibility and potential risk factors in this specific population. The study has also explored potential relationships between diseases and traits based on PGS pairwise correlations, revealing significant correlations that warrant further investigation. These findings have contributed to increase our understanding of the genetic basis of human traits and have implications for personalized medicine and public health interventions in the Spanish population. In addition, for the sake of reproducibility, we provide a data processing pipeline, enabling the computation of PGS for external genomes and exomes. The pipeline, accessible on GitHub, supports parallel tasks on various computing platforms and contributes to the standardization of PGS comparisons globally. Lastly, a user-friendly web interface facilitates the exploration of PGS reference distributions, featuring a detailed table, distribution plots, and filtering options. This interface enhances accessibility for researchers and clinicians, fostering informed decision-making based on population-specific PGS distributions. The PGS reference distributions can be explored at the SpPGS Atlas repository through the web interface: https://csvs.clinbioinfosspa.es/?tab=pgs., This work is supported by Postdoctoral Grant RH-0052-2021 of Rosario Carmona from Junta de Andalucía (Consejería de Salud y Familias), co-funded by the European Union, European Social Fund (FSE) 2014-2020, and also by grants PID2020-117979RB-I00 from the Spanish Ministry of Science and Innovation, IMPaCT-Data IMP/00019 from the ISCIII, co-funded with European Regional Development Funds (ERDF).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

A crowdsourcing database for the copy-number variation of the Spanish population

  • López-López, Daniel
  • Roldán, Gema
  • Fernández-Rueda, José L.
  • Bostelmann, Gerrit
  • Carmona, Rosario
  • Aquino, Virginia
  • Pérez-Florido, Javier
  • Ortuño, Francisco
  • Pita, Guillermo
  • Núñez-Torres, Rocío
  • González Neira, Anna
  • Alonso Sánchez, Ángel Miguel
  • Salgado Garrido, Josefa
  • Pasalodos Sánchez, Sara
  • Ayuso, Carmen
  • Mínguez, Pablo
  • Ávila-Fernández, Almudena
  • Corton, Marta
  • Artuch, Rafael
  • Borrego, Salud
  • Antiñolo, Guillermo
  • Carracedo, Ángel
  • Amigo, Jorge
  • Castaño, Luis Antonio
  • Tejada, Isabel
  • Delmiro, Aitor
  • Espinos, Carmina
  • Grinberg, Daniel
  • Guillén, Encarnación
  • Lapunzina, Pablo
  • López-Escámez, José Antonio
  • Gallego-Martínez, Álvaro
  • Martí, Ramón
  • Rovira, Eulalia
  • Millán, José María
  • Moreno Pelayo, Miguel Ángel
  • Morín, Matías
  • Moreno-Galdó, Antonio
  • Fernández-Cancio, Mónica
  • Morte, Beatriz
  • Mulero, Victoriano
  • García, Diana
  • Nunes, Virginia
  • Palau, Francesc
  • Pérez Pérez, Belén
  • Pérez-Jurado, Luis A.
  • Perona, Rosario
  • Pujol, Aurora
  • Ramos, Feliciano
  • López, Esther
  • Ribes, Antonia
  • Rosell, Jordi
  • Surrallés, Jordi
  • Peña-Chilet, María
  • Dopazo, Joaquín
Background: Despite being a very common type of genetic variation, the distribution of copy-number variations (CNVs) in the population is still poorly understood. The knowledge of the genetic variability, especially at the level of the local population, is a critical factor for distinguishing pathogenic from non-pathogenic variation in the discovery of new disease variants. Results: Here, we present the SPAnish Copy Number Alterations Collaborative Server (SPACNACS), which currently contains copy number variation profiles obtained from more than 400 genomes and exomes of unrelated Spanish individuals. By means of a collaborative crowdsourcing effort whole genome and whole exome sequencing data, produced by local genomic projects and for other purposes, is continuously collected. Once checked both, the Spanish ancestry and the lack of kinship with other individuals in the SPACNACS, the CNVs are inferred for these sequences and they are used to populate the database. A web interface allows querying the database with different filters that include ICD10 upper categories. This allows discarding samples from the disease under study and obtaining pseudo-control CNV profiles from the local population. We also show here additional studies on the local impact of CNVs in some phenotypes and on pharmacogenomic variants. SPACNACS can be accessed at: http://csvs.clinbioinfosspa.es/spacnacs/. Conclusion: SPACNACS facilitates disease gene discovery by providing detailed information of the local variability of the population and exemplifies how to reuse genomic data produced for other purposes to build a local reference database., This work is supported by Grants PID2020-117979RB-I00 from the Spanish Ministry of Science and Innovation; by the Institute of Health Carlos III (project IMPaCT-Data, exp. IMP/00019, IMP/00009 and PI20/01305), co-funded by the European Union, European Regional Development Fund (ERDF, “A way to make Europe”).